Pfizer became the first $100-billion company in the industry in 2022 on the strength of its COVID-19 vaccine and COVID-19 drug. Will its record-breaking results hold in 2023, and how will non-COVID products perform?
Top 10 Key Trends in New Drug Approvals: Small Molecules & Biologics
Economic uncertainty, supply chain, talent management, and risk mitigation were key issues cited by CEOs in PwC’s Global CEO survey, released at the World Economic Forum in Davos, Switzerland. What are key takeaways from a study of 4,400 CEOs?
More coverage of the J.P. Morgan Annual Healthcare Conference in San Francisco earlier this month, where bio/pharma industry executives highlighted their companies’ strategies and key growth initiatives. What are more highlights?
The CDMO/CMO Report: The Year Ahead in Bio/Pharma Outsourcing
What can the markets for bio/pharmaceutical outsourcing expect in 2023? DCAT Value Chain Insights examines key trends and highlights in major manufacturing segments: API and drug-product manufacturing.
Big Pharma Strategies and Growth Initiatives: What’s In Store for 2023
What are the top 10 items on the bio/pharma industry’s watchlist for 2023? To continued inflationary pressures, a looming global recession, to moderating global bio/pharma industry growth, DCAT Value Chain Insights examines what is on the industry’s radar.
There were 37 new molecular entities and therapeutic biologics approved in 2022 by the FDA, significantly down from the 50 new drugs approved in 2021. What were the winners in small molecules and biologics and large and small companies?